Raj Vuppalanchi - Concepedia

Author

Raj Vuppalanchi

Indiana University – Purdue University Indianapolis ORCID

Also Known As

Conjeevaram, Hari S., Danielle Carpenter, Dr. Raj Vuppalanchi, Girish Subbarao, Gopalreddy, Vani, R VUPPALANCHI, R Vuppalanchi, R. Vuppalanchi, Raj K Vuppalanchi, Raj K. Vuppalanchi

357

Publications

15K

Citations

H-Index

131

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis Indiana University School of Medicine National Institutes of Health Virginia Commonwealth University Johns Hopkins University

About

Raj Vuppalanchi is an author at Indiana University – Purdue University Indianapolis specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	52	7.5K
2	Health Sciences	16	19	3.3K
3	Public Health	3	4	581
4	Language Studies	1	1	36
5	Natural Sciences	1	1	85

Raj Vuppalanchi

115

Publications

11.3K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study Naga Chalasani, Herbert L. Bonkovsky, Robert J. Fontana, Gastroenterology Dilin Prospective StudyHepatologyMedicineLiver PhysiologyGastroenterology	2015	872
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis Rohit Loomba, Mark L. Hartman, Eric Lawitz, New England Journal of Medicine	2024	611
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease Mohammad Shadab Siddiqui, Raj Vuppalanchi, Mark L. Van Natta, Clinical Gastroenterology and Hepatology HepatologyMedical ImagingNonalcoholic Fatty Liver DiseaseAbdominal ImagingDiagnosis	2018	580
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network Victor J. Navarro, Huiman X. Barnhart, Herbert L. Bonkovsky, Hepatology	2014	402
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Gastroenterology	2019	326
Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease Sweta Tandra, Matthew M. Yeh, Elizabeth M. Brunt, Journal of Hepatology UrologyMetabolic Associated SteatohepatitisHepatologyMetabolic Associated Steatotic Liver DiseaseNonalcoholic Fatty Liver Disease	2010	311
High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population Eduardo Vilar‐Gómez, Lauren Nephew, Raj Vuppalanchi, Hepatology	2021	274
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage Mohammad Shadab Siddiqui, Goro Yamada, Raj Vuppalanchi, Clinical Gastroenterology and Hepatology FibrosisUterine FibroidsDisease ProgressionMedical ImagingFibrosis Stage	2019	258

Page 1